Can economic analysis contribute to disease elimination and eradication? A systematic review

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sicuri, Elisa ^a   Evans, David B ^b,c   Tediosi, Fabrizio ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROL STRATEGY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE ELIMINATION; DISEASE ERADICATION; DISEASE RE-EMERGENCE; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; GOVERNMENT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; INVESTMENT; LIFE EXPECTANCY; NONHUMAN; PRODUCTIVITY; PUBLIC HEALTH; REIMBURSEMENT; REVIEW; SYSTEMATIC REVIEW; ECONOMICS; META ANALYSIS; MOTIVATION;

DISEASE ERADICATION; HUMANS; MOTIVATION;

EID: 84935501556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130603     Document Type: Review

References (70)

1. Cutler D, Deaton A, Lleras-Muney A. The Determinants of Mortality. Journal of Economic Perspectives. 2006; 20(3):97-120.
2. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013; 382(9908):1898-955. Epub 2013/12/07. S0140-6736(13)62105-4 [pii] doi: 10.1016/S0140-6736(13)62105-4 PMID: 24309475.
3. Barro R. Health and Economic Growth. Annals of Economics and Finance. 2013; 14(2(A)):305-42.
4. Vollmer S, Harttgen K, Subramanyam MA, Finlay J, Klasen S, Subramanian S. Association between economic growth and early childhood undernutrition: evidence from 121 Demographic and Health Surveys from 36 low-income and middle-income countries. The Lancet Global Health. 2014; 2(4). doi: 10.1016/S2214-109X(14)70019-1 PMID: 25103064
5. Subramanyam MA, Kawachi I, Berkman LF, Subramanian SV. Is economic growth associated with reduction in child undernutrition in India? PLoS Med. 2011; 8(3):e1000424. Epub 2011/03/17. doi: 10.1371/journal.pmed.1000424 PMID: 21408084; PubMed Central PMCID: PMC3050933.
6. Health and wealth - Improved health does not always make countries richer. The Economist 2008.
7. Ashraf Q, Lester A, Weil D. When Does Improving Health Raise GDP? In: Acemoglu D, Rogoff K, Woodford M, editors. NBER Macroeconomics Annual 2008: University of Chicago Press; 2009. p. 157-204.
8. Tediosi F, Steinmann P, de Savigny D, Tanner M. Developing Eradication Investment Cases for Onchocerciasis, Lymphatic Filariasis, and Human African Trypanosomiasis: Rationale and Main Challenges. PLoS Negl Trop Dis. 2013; 7(11):e2446. doi: 10.1371/journal.pntd.0002446 PMID: 24244762
9. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases andinjuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197-223. Epub 2012/12/19. S0140-6736(12)61689-4 [pii] doi: 10.1016/S0140-6736(12)61689-4 PMID: 23245608.
10. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, et al. Shrinking the malaria map: progress and prospects. Lancet. 2010; 376(9752):1566-78. Epub 2010/11/03. S0140-6736(10)61270-6 [pii] doi: 10.1016/S0140-6736(10)61270-6 PMID: 21035842; PubMed Central PMCID: PMC3044848.
11. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution, and interventions for infectious diseases of poverty. Infect Dis Poverty. 2014; 3:21. Epub 2014/08/12. doi: 10.1186/2049-9957-3-212049-9957-3-21 [pii]. PMID: 25110585; PubMed Central PMCID: PMC4126350.
12. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011; 8(1):e1000406. Epub 2011/02/12. doi: 10.1371/journal.pmed.1000406 PMID: 21311579; PubMed Central PMCID: PMC3026687.
13. Dowdle WR, Cochi SL. The principles and feasibility of disease eradication. Vaccine. 2011; 29 Suppl 4:D70-3. Epub 2011/12/23. S0264-410X(11)00516-0 [pii] doi: 10.1016/j.vaccine.2011.04.006 PMID: 22188936.
14. World Health Organization. Global measles and rubella strategic plan: 2012-2020. Geneva: World Health Organization, 2012. doi: 10.1016/j.vaccine.2012.11.094 PMID: 24304830
15. WHO polio weekly global surveillance update. Global Polio Eradication Initiative. http://www.polioeradication.org/ Accessed 17 December 2014.
16. World Health Organization. Global malaria control and elimination: report of a technical review (17-18 January 2008). Geneva: Switzerland 2008.
17. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. Executive Summary. Geneva: World Health Organization, 2012.
18. Caplan AL. Is disease eradication ethical? Lancet. 2009; 373(9682):2192-3. Epub 2009/07/08. PMID: 19582890.
19. Barrett S. Economic considerations for the eradication endgame. Philos Trans R Soc Lond B Biol Sci. 2013; 368(1623):20120149. Epub 2013/06/27. rstb.2012.0149 [pii] doi: 10.1098/rstb.2012.0149 PMID: 23798697; PubMed Central PMCID: PMC3720047.
20. Andreano R. Economic issues in disease control and eradication. Soc Sci Med. 1983; 17(24):2027-32. Epub 1983/01/01. PMID: 6670006.
21. Gyldmark M, Alban A. Economic evaluation of programmes aiming at eradicating infectious diseases. Health Policy. 1998; 45(1):69-79. Epub 1998/06/06. doi: S0168-8510(98)00032-3 [pii]. PMID: 10183014.
22. Sabot O, Cohen JM, Hsiang MS, Kahn JG, Basu S, Tang L, et al. Costs and financial feasibility of malaria elimination. Lancet. 2010; 376(9752):1604-15. Epub 2010/11/03. S0140-6736(10)61355-4 [pii] doi: 10.1016/S0140-6736(10)61355-4 PMID: 21035839; PubMed Central PMCID: PMC3044845.
23. Ramzy RM, Goldman AS, Kamal HA. Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J. 2005; 4:7. Epub 2005/08/04. 1475-2883-4-7 [pii] doi: 10.1186/1475-2883-4-7 PMID: 16076397; PubMed Central PMCID: PMC1187908.
24. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis. 2010; 4(6):e708. Epub 2010/06/10. doi: 10.1371/journal.pntd.0000708 PMID: 20532228; PubMed Central PMCID: PMC2879371.
25. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, Garshong B, et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis. 2007; 1(1):e67. Epub 2007/11/09. doi: 10.1371/journal.pntd.0000067 PMID: 17989784; PubMed Central PMCID: PMC2041814.
26. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet. 2010; 376(9745):953-4. Epub 2010/09/21. S0140-6736(10)61442-0 [pii] doi: 10.1016/S0140-6736(10)61442-0 PMID: 20851250.
27. Sleigh A, Jackson S, Li X, Huang K. Eradication of schistosomiasis in Guangxi, China. Part 2: Political economy, management strategy and costs, 1953-92. Bull World Health Organ. 1998; 76(5):497-508. Epub 1998/12/30. PMID: 9868841; PubMed Central PMCID: PMC2305779.
28. Huda MM, Hirve S, Siddiqui NA, Malaviya P, Banjara MR, Das P, et al. Active case detection in national visceral leishmaniasis elimination programs in Bangladesh, India, and Nepal: feasibility, performance and costs. BMC Public Health. 2012; 12:1001. Epub 2012/11/21. 1471-2458-12-1001 [pii] doi: 10.1186/1471-2458-12-1001 PMID: 23164318; PubMed Central PMCID: PMC3533526.
29. Naik SS, Ganapati R. Socioeconomics of a global leprosy eradication programme. Pharmacoeconomics. 1998; 13(6):677-86. Epub 1998/05/07. PMID: 10179703.
30. Levin A, Burgess C, Garrison LP Jr., Bauch C, Babigumira J, Simons E, et al. Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis. 2011; 204 Suppl 1:S98-106. Epub 2011/06/17. jir096 [pii] doi: 10.1093/infdis/jir096 PMID: 21666220.
31. Babigumira JB, Levin A, Burgess C, Garrison LP Jr., Bauch CT, Braka F, et al. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. J Infect Dis. 2011; 204 Suppl 1:S116-23. Epub 2011/06/17. jir132 [pii] doi: 10.1093/infdis/jir132 PMID: 21666152.
32. Acharya A, Diaz-Ortega JL, Tambini G, de Quadros C, Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine. 2002; 20(27-28):3332-41. Epub 2002/09/06. doi: S0264410X02002967 [pii]. PMID: 12213403.
33. Miller MA, Redd S, Hadler S, Hinman A. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine. 1998; 16(20):1917-22. Epub 1998/10/31. doi: S0264410X9800125X [pii]. PMID: 9796043.
34. Bishai D, Johns B, Lefevre A, Nair D, Simons E, Dabbagh A. Measles Eradication versus Measles Control: An Economic Analysis. Vaccines & Vaccination 2012; 8(3).
35. Kim A, Tandon A, Ruiz-Tiben E. Cost-Benefit Analysis of the Global Dracunculiasis Eradication Campain. Washington: The World Bank, 1997.
36. Adhikari SR, Supakankunti S. A cost benefit analysis of elimination of kala-azar in Indian subcontinent: an example of Nepal. J Vector Borne Dis. 2010; 47(3):127-39. Epub 2010/09/14. PMID: 20834081.
37. Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol. 2002; 191(2):89-96. Epub 2002/11/01. doi: 10.1007/s00430-002-0123-4 PMID: 12410347.
38. Brown PJ. Socioeconomic and demographic effects of malaria eradication: a comparison of Sri Lanka and Sardinia. Soc Sci Med. 1986; 22(8):847-59. Epub 1986/01/01. PMID: 3529423.
39. Lucas A. The impact of malaria eradication on fertility. Economic Development and Cultural Change. 2013; 61(3):607-31.
40. Barofsky J, Chase C, Anekwe T, Farzadfar F. The economic effects of malaria eradication: Evidence from an intervention in Uganda. 2011.
41. Cutler D, Fung W, Kremer M, Singhal M, Vogl T. Early-life malaria exposure and adult outcomes: Evidence from malaria eradication in India. American Economic Journal: Applied Economics. 2010; 2(72).
42. Bleakely H. Malaria eradication in the Americas: A retrospective analysis of childhood exposure. American Economic Journal: Applied Economics. 2010; 2(1). PMID: 20582231
43. Bleakely H. Disease and development: Evidence from Hookworm eradication in the American South. The Quarterly Journal of Economics 2007;February 122(1):73-117. PMID: 24146438
44. Lucas A. Malaria eradication and educational attainment: Evidence from Paraguay and Sri Lanka. American Economic Journal: Applied Economics. 2010; 2(46). PMID: 23946866
45. Modrek S, Liu J, Gosling R, Feachem RG. The economic benefits of malaria elimination: do they include increases in tourism? Malar J. 2012; 11:244. Epub 2012/07/31. 1475-2875-11-244 [pii] doi: 10.1186/1475-2875-11-244 PMID: 22839351; PubMed Central PMCID: PMC3470964.
46. th century. Journal of International Development. 2008; 20:1080-106.
47. Mas-Colell A, Whinston M, Green J. Microeconomic Theory. OUP USA, editor1995.
48. Barrett S. Eradication versus control: the economics of global infectious disease policies. Bull World Health Organ. 2004; 82(9):683-8. Epub 2005/01/05. PMID: 15628206; PubMed Central PMCID: PMC2622975.
49. Barrett S. The smallpox eradication game. Public Choice. 2006; 130:179-207.
50. Barrett S. Optimal disease erradication. Environment and Development Economics. 2007; 12:627-52.
51. Barrett S. Stop! The polio vaccination cessation game. The World Bank Economic Review. 2011.
52. Shaffer G. International Law and Global Public Goods in a Legal Pluralist World. The European Journal of International Law. 2012; 23(3):669-93
53. Barham T, Maluccio JA. Eradicating diseases: The effect of conditional cash transfers on vaccination coverage in rural Nicaragua. J Health Econ. 2009; 28(3):611-21. Epub 2009/02/24. S0167-6296(09)00002-2 [pii] doi: 10.1016/j.jhealeco.2008.12.010 PMID: 19233495.
54. Geoffard P, Philipson T. Disease Eradication: Private versus Public Vaccination. American Economic Review. 1997; 87(1).
55. Chesson H, Owusu-Edusei K Jr. Examining the impact of federally-funded syphilis elimination activities in the USA. Soc Sci Med. 2008; 67(12):2059-62. Epub 2008/10/28. S0277-9536(08)00486-3 [pii] doi: 10.1016/j.socscimed.2008.09.049 PMID: 18952341.
56. Mangham LJ, Hanson K. Scaling up in international health: what are the key issues? Health Policy Plan. 2010; 25(2):85-96. Epub 2010/01/15. czp066 [pii] doi: 10.1093/heapol/czp066 PMID: 20071454.
57. Sen A. Development as Freedom. New York1999.
58. Roemer J. A Pragmatic Theory of Responsibility for the Egalitarian Planner. Philosophy & Public Affairs. 1993; 22(2):146-66.
59. Shah NK. Assessing strategy and equity in the elimination of malaria. PLoS Med. 2010; 7(8):e1000312. Epub 2010/08/07. doi: 10.1371/journal.pmed.1000312 PMID: 20689859; PubMed Central PMCID: PMC2914633.
60. Steketee RW, Eisele TP. Is the scale up of malaria intervention coverage also achieving equity? PLoS One. 2009; 4(12):e8409. Epub 2009/12/23. doi: 10.1371/journal.pone.0008409 PMID: 20027289; PubMed Central PMCID: PMC2791860.
61. Noor AM, Amin AA, Akhwale WS, Snow RW. Increasing coverage and decreasing inequity in insecticide-treated bednet use among rural Kenyan children. PLoS Med. 2007; 4(8):e255. Epub 2007/08/24.07-PLME-RA-0227 [pii] doi: 10.1371/journal.pmed.0040255 PMID: 17713981; PubMed Central PMCID: PMC1949846.
62. Hanvoravongchai P, Mounier-Jack S, Oliveira Cruz V, Balabanova D, Biellik R, Kitaw Y, et al. Impact of measles elimination activities on immunization services and health systems: findings from six countries. J Infect Dis. 2011; 204 Suppl 1:S82-9. doi: 10.1093/infdis/jir091 PMID: 21666218.
63. Griffiths UK, Mounier-Jack S, Oliveira-Cruz V, Balabanova D, Hanvoravongchai P, Ongolo P. How can measles eradication strengthen health care systems? J Infect Dis. 2011; 204 Suppl 1:S78-81. doi: 10.1093/infdis/jir090 PMID: 21666217.
64. Bart KJ, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Organ. 1996; 74(1):35-45. Epub 1996/01/01. PMID: 8653814; PubMed Central PMCID: PMC2486843.
65. Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective. Vaccine. 2003; 21(7-8):702-5. Epub 2003/01/18. doi: S0264410X02005844 [pii]. PMID: 12531344.
66. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007; 369(9570):1363-71. Epub 2007/04/24. S0140-6736(07)60532-7 [pii] doi: 10.1016/S0140-6736(07)60532-7 PMID: 17448822.
67. Michael E, Malecela MN, Zervos M, Kazura JW. Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes. PLoS One. 2008; 3(8):e2936. Epub 2008/08/14. doi: 10.1371/journal.pone.0002936 PMID: 18698350; PubMed Central PMCID: PMC2490717.
68. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2010; 29(2):334-43. Epub 2010/10/30. S0264-410X(10)01495-7 [pii] doi: 10.1016/j.vaccine.2010.10.026 PMID: 21029809.
69. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviraltherapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009; 373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9 PMID: 19038438.
70. Huldén L, McKitrick R, Huldén L. Average Household Size and the Eradication of Malaria. Ontario 2012.